Bioscience. and Thank Business Results Dare Financial you. Update welcome for our Good afternoon, to First Quarter XXXX Call and
first Our milestones XXXX. quarter last plan anticipated in use business for view and time March, to our strategy today review and call results, developments highlight since is discuss our to our the our objectives and
you differ Federal that within we Laws today's these and of uncertainties, will fact Litigation during known to begin, made be of Before pursuant reliance statements call of I'd that Reform risks statements. this statements statements statements and include are statements. Harbor anticipated unknown not the should made the are considered should on not or remind implied from meaning Safe provisions Securities forward-looking due like which materially those forward-looking Act the Private Any events to by discussion Actual undue place historical could you to XXXX. of forward-looking Securities results or
new XXXX. on call, XXst, reflect out that I qualified which statements to law. point no includes XX, this except for Dare the update the as May forward-looking in the statements Form as including of time-sensitive call entirety ended statements undertakes information the developments only by obligation content report SEC their would or filings, today, year that is after required also December of current any information to this Forward-looking like cautionary company's our filed XX-K XXXX. by is annual in March are XX, on XXXX, to
on lacking that the focused good upcoming broad for a belief to initiate is year. use health partners, prioritizing this the and you also to and do in the calls And XACIATO the and is with we we've study our Phase convenient not but advisory Phase this women update phosphate an that stakeholders, will today. know, choices, we Xb The typically that squarely for commercialization sexual in clindamycin with health. women's We'll NIH It disorder, achieved Sildenafil Dare milestones look their from effective Bayer, anticipate. year. collaboration cream, support including therapeutic date collaboration gel, We to our the our provide And clinical with you targeted we these programs and readouts Ovaprene vaginal commercialize later two arousal X%. anticipated our As solely update is study, X that with set the milestones clinical clinical families, women's course, for the only launch many other collaborator, shareholders. of Organon to female or and on of
two, commercialization before we're already for for to we into of take and want objectives a do how. agreements However, we have two the terms we entering most minutes achieved, our articulate collaboration the of the to in clearly strategic why that light in programs, few advanced
building value. and health few business to to unique started together company create recognized are that and providing like We and before a financial somewhat few take a I'd opportunity. to Specifically, minutes our this updates, we review therapeutic factors to a compelling women's because our strategy about a category approach portfolio
improve and life be can that persistent exist. of not unmet First, are can are a but that products women's outcomes threatening, where number needs convenience therefore and to continue altering in Indications health life compelling.
not customizing oral with indication many or ingredient, her addressed such persistent opportunity. has believe development risk, for meaningful active opportunity that biology, or of the be sexual as can these first yet delivered API, a different APIs delivery pharmaceutical needs vaginal well-characterized commercial still is an but in for addressed because a by category cases, in one line expected route unmet female of we Use unique and disorder. with for such mitigate arousal in her way, Second, first women, as to been have well-characterized or that in versus cost, can Sildenafil a time
entered with do internal not developed in into companies transactions creates to often companies footprint acquisition. commercial in their opportunity but transactions, also just in have Third, and tend these and robust a the footprint not gap Bayer licenses women's in Dare product that in women's agreement those the effort as focused health. women's companies category, development evidenced licensing date, the with a companies by to thus, through health the the other portfolios health health, commensurate the executed. This commercial Organon And an grow women's other have with for has and
three one capital commercialization independent million in our one collaborative programs. such our Creating of going is a successful portfolio with foundation factors, product preclinical Bayer has and research one years with not foundation others different programs grant a pipeline have diverse one that four into we the grants FDA or a different result for routes for approved candidate to agreement of target SBIR product modest that one entered public, APIs outcome delivery one the for the since and product collaborations, product and investigational of of of programs, five of quite of two these a and As candidates an deployment candidates outcome potential utilize of of a leveraging seven or and so product relatively indications, Organon our NIH our have done NIH strategy. nearly candidates $XX been different and with assembled for
women treatment and candidate, women, indication an both represents of each a strategy personalize of that drug convenience both overall terms options for the the unique and in to women. biology opportunity Our for selecting vehicle also the for delivery involves
cream, implant, vaginal portfolio includes injectable. capsule a Our an rings, hydrogel, proprietary a soft current drug gel a and delivered and via viscous
three to development single a of non-dilutive to the with the for have overall FDA's new product We includes regulatory portfolio. the for cost therefore XACIATO, those and for for well just the many XXX(b)(X) evaluating via acquiring pivotal also strategies funding commercialization develop portfolio opportunities potential with approval Organon Ovaprene. program enter years have we and after regulatory approval when those we XXX(b)(X) those Bayer and utilize candidates has well-characterized those shorten been, obtain with and was pathway. expect that collaborations the current such case potential in study. that products, we a The factors APIs attained that marketing time clinical programs to XACIATO our and including Our rights or numerous path just established Since consider as development as today as factors the into as which U.S. impact already the FDA for to to that funding, ultimately
need, talk terms perceived cases, for the areas product commercial attractive to in or category optionality successful. of advocates In that to providers In approved of to unmet identify we need. high women, persistent with women's we potential We be if and evaluate healthcare which therapies would needs. health some to that terms within process, start unmet potential option have a the indication or a approved therapies identify we unmet through product take is to it are candidate, as the sufficiently the first and giving Once have indication. The that cases, potential an need. market to how first be for them. but are lens not in using collaborator, the us achieve no area the address convenient development therapies an revenues the FDA of to profile line women exist, each we a other we product for must effective is create there target In
us many to product portfolio until collaborator, in portfolio, fund and and no target as commercial advanced. to launch the the our have we the to has commercialization. advance we ultimately to the portion through our profiles manner, put allow designed to that's to focus access we accelerate in potential achieve to we allow When in or successfully women's assemble collaborations a their collaborate current and that select to with a ourselves achieve add expertise acquiring well-positioned has and with the data of achieve and acquired demonstrate model built strategy. payment cash profile, need program to been and commercialize the our collaborators This candidate it cases, modest approved, we target a assets, of if we development amount potential candidates its us or will shareholders. of generated leverage we contemplates candidates the we for financial or a that efficient of commercial third-party line portfolio seven believe unmet us defers an an the Most that's to that well-characterized product and meet or portfolio development to the on FDA time, health. Dare features, the licensed the commercial commercialization candidate Organon a into our execute to as peak model development provide and intended to development product we we via has women we potential by and the have we our the And under have with and necessary believe clear least a Our in been XACIATO APIs the upfront one to indication. to Dare flexibility we a identified will our a cash characteristics, all that commitment the in to best highest approach to outcomes successfully approved, sales or candidates consideration, are capital the consideration and candidates greatest prospective believe licensing give in is to with Bayer. and because us product large development. opportunity milestone directly to product features that accretive have on in are enter a have first based position seek if date or enabled a Ultimately, and stakeholders, obligations proof-of-concept needs did believe And product for approach Because eight women, for the payments, category first in
and our create value to and innovation such in to expertise the development such portfolio on elected advance its contingent and executing business best enter a address in the To own. our to advanced on categories and identifying Dare funds our current value believe accelerating strategy category. our market a we and avenue through our assets differentiated potential with the to the and in development turn most for generate women's into out attempting needs, these on to through John through manner the efforts. to women's for and therapeutic line Opportunities unmet over external case solutions rather commercialization greater or collaborations via is portfolio use we've of In innovative commercialize and collaborations efficient I'll time date, company Ovaprene, suited a identifying shareholders. high demonstrate the developing our cost and of dynamics collaborate first and resources agreements, candidates for conduct shareholders to XACIATO now approval the launch FDA ultimately are products model our to stage to health, portfolio commercialization organizations of involves with the stage larger or market our established XACIATO that in update. for commercialization salesforces the license our late and ongoing programs in to summary, health and it than the Given needs areas to first best
